Source: CyberAgent, Inc.

Source

BEIJING and BRIDGEWATER, N.J., June 12, 2026 /PRNewswire/ — Gan & Lee Pharmaceuticals (hereinafter “Gan & Lee”, stockcode: 603087.SH) announced that two of its core pipeline products in the fields of diabetes and obesity treatment have recently achieved positive clinical results.

SUPER-3: Insulin Ludefen (GZR4)combined with insulin aspart demonstrated superior HbA1c reduction in adults previously treated with basal-bolus insulin or premixed/dual insulin analogs.

Insulin Ludefen is an investigational ultra-long-acting once-weekly basal insulin analog independently developed by Gan & Lee Pharmaceuticals. The drug’s pivotal Phase III clinical trial in China, SUPER-3, recently met its pre-specified primary endpoint.

SUPER-3 is a 26-week, treat-to-target, Phase 3 clinical trial conducted at 80 medical sites across China (ClinicalTrials.gov Identifier: NCT06767761). The study enrolled 596 adults with type 2 diabetes (T2DM) who had previously been treated with basal-bolus insulin, premixed insulin analogs or dual insulin analog. It evaluated once-weekly Insulin Ludefen compared with once-daily insulin glargine U100  (Lantus^®) injection, both in combination with insulin aspart, with or without non-insulin antidiabetic agents.

The study met its primary endpoint. In patients with T2DM previously treated with mealtime insulin aspart, premixed insulin analogs, or dual insulin analogs, once-weekly Insulin Ludefen, used as the basal insulin component in combination with prandial insulin aspart, demonstrated superior HbA1c reduction versus once-daily insulin glargine U100. After 26 weeks of treatment, compared with the once-daily glargine insulin U100 regimen, the once-weekly Insulin Ludefen demonstrated superiority in reducing HbA1c levels (change from baseline: −1.58% vs. −1.41%); the estimated between-group treatment difference was −0.17%, and this difference was statistically significant (p=0.0021, <0.025). Additionally, Insulin Ludefen demonstrated a higher rate of safe glycemic target attainment: the once-weekly Insulin Ludefen group outperformed the once-daily insulin glargine U100 group on the clinically relevant composite endpoint of achieving HbA1c < 7.0% or ≤ 6.5% without clinically significant (level 2) or severe (level 3) hypoglycemia during the last 12 weeks.

Once-weekly Insulin Ludefen demonstrated a favorable safety and tolerability profile, with no severe (level 3) hypoglycemic events occurring in the Insulin Ludefen group, while three severe (level 3) hypoglycemic events were reported in the insulin glargine U100 group.

The SUPER-3 study focused on a more complex patient population. Compared with insulin-naive patients or those treated with basal insulin alone, patients treated with basal-bolus insulin, premixed insulin analogs, or dual insulin analogs typically had a longer disease duration, more complex treatment regimens, and a heavier daily injection burden. The positive results of the SUPER-3 study further expand the clinical evidence for Insulin Ludefen in patients at different stages of type 2 diabetes treatment, providing key support for the use of once-weekly basal insulin in intensive treatment settings.

Detailed results from the SUPER-3 study are scheduled to be presented at upcoming scientific conferences and published in international academic journals.

About the SUPER Clinical Program

The SUPER program is a large-scale global phase 3 clinical development program for Insulin Ludefen, a proposed once-weekly basal insulin by Gan & Lee. To date, four phase 3 clinical trials have been initiated in China:

SUPER-1: A 52-week trial enrolling 588 insulin-naïve adults with T2DM, comparing the efficacy and safety of once-weekly Insulin Ludefen versus once-daily insulin glargine U100 (Lantus^®), both in combination with non-insulin anti-diabetic treatment. Key results after 26 weeks of treatment showed that once-weekly Insulin Ludefen was superior to once-daily glargine insulin U100 in reducing HbA1c.

SUPER-2: A 26-week trial enrolling 631 adults with T2DM previously treated with basal insulin, comparing the efficacy and safety of once-weekly Insulin Ludefen versus once-daily insulin degludec (Tresiba^®), with or without concomitant non-insulin anti-diabetic treatment. Key results showed that once-weekly Insulin Ludefen was superior to once-daily degludec in reducing HbA1c.

Bofanglutide injection: Key Phase 3 Study in China Meets Primary Endpoint

The GRADUAL-1 study is a multicenter, randomized, double-blind, placebo-controlled Phase 3 clinical study conducted in adults with overweight or obesity in China (ClinicalTrials.gov Identifier: NCT06728124). The study enrolled 640 participants who were randomized to receive bofanglutide injection 24 mg, bofanglutide injection 48 mg , or placebo once every two weeks (Q2W) for 52 weeks. Participants had a mean baseline body weight of 93.71 kg and a mean body mass index (BMI) of 33.28 kg/m², with baseline characteristics generally well-balanced across treatment groups.

The results showed that after 52 weeks of treatment, participants receiving bofanglutide injection 24 mg and 48 mg achieved mean body weight reductions of 15.12% and 18.54%, respectively, compared with 1.11% in the placebo group. In addition, 91.8% and 98.1% of participants in the bofanglutide injection 24 mg and 48 mg groups, respectively, achieved at least 5% weight loss from baseline.

In addition, bofanglutide injection also showed comprehensive improvements in cardiovascular and metabolic parameters, including waist circumference, blood pressure, triglycerides, and serum uric acid.

Regarding safety, bofanglutide injection was generally well tolerated in both the 24 mg and 48 mg groups. The safety profile was consistent with that of other GLP-1 RAs. The most common adverse events were gastrointestinal reactions and were mostly mild to moderate and transient, with no new safety signals identified.

Meanwhile, a Phase 2 clinical trial evaluating the efficacy and safety of bofanglutide injection in overweight and obese participants in the United States has also met its primary endpoint.

This Phase 2 clinical study (NCT06737042) was a multicenter, randomized, controlled study that enrolled a total of 326 participants across 20 clinical trial sites in the United States. Bofanglutide injection and placebo were administered under double-blind conditions, while tirzepatide injection served as an open-label comparator. The study evaluated the efficacy and safety of bofanglutide injection in adult participants who had inadequate weight control despite lifestyle interventions and had either a BMI > 30 kg/m², or a BMI ≥ 27 kg/m² accompanied by weight-related comorbidities (excluding type 2 diabetes). Participants were randomized to receive bofanglutide injection 24 mg, 36 mg, or 48 mg Q2W or placebo, or 15 mg of tirzepatide injection once weekly for 36 weeks (including a dose-escalation phase).

After 36 weeks of treatment, among participants with overweight/obesity without type 2 diabetes, the 48 mg bofanglutide injection group achieved an average weight loss of 15.18%, with no weight loss plateau observed; the 15 mg tirzepatide injection group achieved a mean weight reduction of 16.93%. Bofanglutide injection also demonstrated significant improvements in cardiovascular and metabolic parameters, including blood pressure, waist circumference, and serum uric acid levels. The most common adverse events were gastrointestinal in nature, including nausea, vomiting, and diarrhea; these events were generally mild and transient, and no new safety signals were identified.

The Insulin Ludefen SUPER-8 study (a head-to-head comparison with insulin icodec) and other studies in the GRADUAL clinical program of bofanglutide injection are currently underway. Detailed results from these two studies are scheduled to be presented at future scientific conferences and published in international academic journals.

Source

PERTH, Australia, June 12, 2026 /PRNewswire/ — Church leaders from across the City of Wanneroo gathered with Mayor Linda Aitken on Friday 12 June for the Wanneroo Prayer Breakfast, held at the Wanneroo Civic Centre, coming together to pray for the city and hear first-hand about the challenges facing Western Australia’s fastest growing community.

The City of Wanneroo is the fastest growing local government area in Western Australia, taking in 36 suburbs stretching from Koondoola and Alexander Heights in the south to Yanchep and Two Rocks in the north. As the region grows, so do the pressures on households and neighbourhoods — and the breakfast focused on how churches and local government can work together to address the challenges facing people across the city and serve their neighbours.

Mayor Aitken thanked church leaders for their contribution to the community, telling Bruce Chant, who leads Kingdomcity’s Butler campus:

“Thank you for all the work you’re doing to add value to the City of Wanneroo. It’s great to see the churches engaging with the community. We are so happy with our partnership with churches like Kingdomcity to serve the people in our city.”

In her address, the Mayor called for a united effort across her city.

“We are all encouraged to lift people up, loving one another, caring for our community. Together, we must make a lasting difference,” she said.

Nick Scott, who led Mt Pleasant Baptist Church for 29 years, spoke about the unity among Christian churches across the city and their shared commitment to working together for its people, while Ben Gould of the Love Our Suburb initiative from C3 Hepburn Heights closed the gathering by praying a blessing over the people of the city.

Troy Anderson from Kingdomcity in Wangara said the breakfast reflected a genuine sense of hope for the region.

“It was amazing to see leaders and people from different churches and denominations come together to pray for our city,” Pastor Anderson said. “Moments like this remind us that we’re stronger when we work together. I love being part of what God is doing in our community, and I believe as we continue to serve, love people and bring hope, we’ll see lasting change across our city.”

Kingdomcity’s Wangara and Butler campuses serve communities across the City of Wanneroo and form part of the church’s seven campuses across Perth.

About Kingdomcity:

Kingdomcity is a global Christian church movement founded in 2006 by Pastor Mark Varughese. The largest church in Perth, with 20,000 people attending its seven campuses across the city and more than 70,000 across 47 locations globally, Kingdomcity exists to connect, equip and empower people to bring the reality of God to their world.

Source

HAIKOU, China, June 12, 2026 /PRNewswire/ — A news report from chinadaily.com.cn

The Hainan provincial government invited a group of 15 from Hong Kong — including media professionals, the city’s Legislative Council members, cultural and tourism key opinion leaders and online content creators — to take part in a six-day in-depth media tour of the tropical province.

The media tour, formally titled “Chasing Aerospace Dreams, Embracing Hainan FTP: 2026 Hong Kong Media Talents Exchange & Interview Event”, was launched at a ceremony in Haikou, capital of China’s southernmost Hainan province on June 9.

At the launch ceremony, the Hainan Provincial Department of Tourism, Culture, Radio, Film and Sports presented 10 participants with certificates that appointed them as 2026 Hainan International Tourism Promotion Ambassadors.

They are expected to use their media platforms and influence to promote Hainan’s tourism resources and showcase the island province’s tremendous appeal to global audiences. In total, the 15 participants collectively reach an audience of over 1 million followers across platforms including Instagram, YouTube, Facebook and TikTok — making them an important channel connecting Hainan with Hong Kong and international visitors.

The media group will visit Qionghai, Wanning, Wenchang, Lingshui and other destinations for firsthand exploration and experience of the development of the Hainan Free Trade Port, in a bid to present a panoramic view of the FTP’s achievements through the lens of Hong Kong media influencers and to further promote cultural exchanges and cooperation between Hainan and Hong Kong.

Source

Luxury hospitality leaders from across Asia-Pacific gather in Seoul for LHW’s Regional Membership Meeting of 2026

• LHW, the world’s largest collection of independent luxury hotels, admits only properties that meet its rigorous quality standards.
• The meeting at Yeong Bin Gwan, The Shilla Seoul’s signature event venue, was attended by LHW President and CEO Shannon Knapp on her first visit to South Korea.
• The event highlighted The Shilla Seoul’s more than 45-year partnership with LHW and reinforced its standing as one of Korea’s leading luxury hotels.

SEOUL, South Korea, June 12, 2026 /PRNewswire/ — The Shilla Seoul hosted the 2026 Asia-Pacific Membership Meeting of The Leading Hotels of the World (LHW), marking the first time the annual gathering was held at The Shilla Seoul.

The Shilla Seoul, operated by The Shilla Hotels & Resorts, the hotel business arm of Hotel Shilla, a Samsung Group affiliate, welcomed LHW members and luxury hospitality leaders from across the Asia-Pacific region at the meeting. Attendees included LHW President and CEO Shannon Knapp and senior executives from member hotels and the organization, who gathered in Seoul to discuss market trends, strategic priorities, and future opportunities for the luxury travel industry.

Founded in New York in 1928, LHW is the world’s largest collection of independent luxury hotels. Membership is reserved for properties that meet the organization’s rigorous quality standards. Today, LHW represents more than 425 luxury hotels across over 80 countries worldwide.

The Shilla Seoul has maintained its membership with LHW for more than 45 years since opening its doors. The hotel continues to strengthen its position as one of Korea’s leading luxury hospitality destinations through partnerships with globally recognized travel and hospitality organizations, including Forbes Travel Guide, Michelin Guide, and Virtuoso.

Held annually, the LHW Asia-Pacific Membership Meeting serves as a platform for member hotels across the region to exchange industry insights, discuss emerging trends, and explore future growth opportunities. The meeting also welcomed Shannon Knapp, President and CEO of LHW, on her first visit to South Korea, underscoring the growing significance of Seoul within the global luxury travel market.

Hosted at Yeong Bin Gwan, The Shilla Seoul’s signature event venue, the gathering provided attendees with an immersive experience of Korean heritage and culture through its contemporary interpretation of traditional Korean architecture.

“It has been a great honor to gather with nearly 60 hoteliers representing more than 30 member hotels across our Asia-Pacific Membership Meetings. The first week of meetings culminated at The Shilla Seoul, a long-standing LHW member known for its exemplary Korean hospitality,” said Shannon Knapp, President and CEO of LHW. “As a vital region for LHW, Asia-Pacific continues to be a source of innovation, growth, and engagement. We look forward to building on the momentum, relationships, and ideas generated through these discussions at The Shilla Seoul and throughout the region.”

The Shilla Seoul continues to earn recognition from leading international hospitality rating organizations and luxury travel networks, further strengthening its reputation as one of Korea’s premier luxury hotels.

In February 2026, The Shilla Seoul was awarded the Forbes Travel Guide Five-Star rating for the eighth consecutive year, becoming the first and only hotel in Korea to achieve this distinction. The hotel was also named to Forbes Travel Guide’s Exclusive Group, a recognition reserved for just 51 properties worldwide that demonstrate exceptional service excellence.

In addition, The Shilla Seoul was ranked the No. 1 hotel in South Korea in La Liste Top 1000 Hotels 2025 and was included among the World’s Top 200 Hotels, further underscoring its standing among the world’s leading luxury hospitality destinations.

As global attention toward South Korea continues to grow, the selection of The Shilla Seoul as the host of one of LHW’s Asia-Pacific Membership Meetings highlights both Seoul’s rising profile as a luxury travel destination and The Shilla Seoul’s enduring leadership within Korea’s luxury hospitality industry.

###

About Hotel Shilla 

Hotel Shilla, an affiliate of the Samsung Group, is a leading hospitality and travel retail operator based in South Korea, committed to delivering outstanding customer experiences through innovation and service excellence. Its hospitality division, The Shilla Hotels & Resorts, includes three hotel brands: The Shilla, Shilla Monogram, and Shilla Stay, with 22 properties across South Korea, China and Vietnam. The Shilla Seoul, the company’s flagship luxury property, is a member of the Leading Hotels of the World (LHW) and an APAC Regional Program Partner of Virtuoso, recognized globally for excellence in service and sophistication. In its travel retail division, The Shilla Duty Free is a leading duty-free powerhouse, operating three domestic stores, two overseas branches, and an online platform. Drawing on decades of expertise, Hotel Shilla continues to pursue new opportunities for growth, aiming to become a world-class service distribution leader.

For more information visit: www.shilla.net/seoul, Instagram at @theshillaseoul, LinkedIn at @theshillaprteam

About The Leading Hotels of the World, Ltd. (LHW)

In 1928, 38 independent hoteliers came together to create LHW which now comprises more than 425 hotels in over 80 countries, making it the largest collection of independent luxury hotels. Since its inception, the Company has carefully curated a selection of distinctive hotels, resorts, inns, chalets, villas, and safari camps, from the snow-capped Alps of Europe to the African veldt, to share them with adventurous souls who seek the remarkably uncommon. The LHW community is made of exceptional individuals, united by a passion for the surprising discoveries and details that come with every travel experience. LHW hoteliers are artisans of hospitality whose expertise, commitment to excellence and individual flair allows them to create story-worthy moments for their guests. It is these authentic, individualized moments, combined with the warm high-touch service these hoteliers and their team provide, that keeps discerning travelers returning again and again. LHW’s collection covers the globe and promises a broad range of destinations and unique experiences, enhanced by LHW’s tiered guest loyalty program, Leaders Club. From converted former palaces and countryside retreats run by the same families for generations, to gleaming skyscrapers in dynamic urban centers, serene private island escapes, glamorous tented camps – and beyond – travelers are invited to explore, find inspiration, and experience unforgettable travel moments.

For more information visit: www.lhw.com, Facebook at @LeadingHotels, Twitter at @LeadingHotels and Instagram @leadinghotelsoftheworld.

Source

The palm-sized cordless reciprocating detail sander is now available on Amazon, with direct sales on HOZO’s official website beginning June 5, 2026.

HONG KONG, June 11, 2026 /PRNewswire/ — HOZO has announced the global retail launch of NeoSander, a compact reciprocating detail sander developed for precision finishing in model making, DIY projects, and other detail-oriented creative work.

The launch follows a Kickstarter campaign that raised more than US$2 million from over 14,000 backers, reflecting strong international interest in compact, precision-focused tools for makers and hobbyists.

The tool uses a patented linear motor system delivering up to 13,000 strokes per minute. Unlike rotary sanders, its linear motion helps reduce circular scratch patterns and provides more control when working on fine or delicate surfaces.

Compact and cordless, NeoSander is designed for use in areas where larger tools are difficult to handle. It comes with interchangeable sanding heads intended for edges, corners, curves, and other hard-to-reach surfaces.

Typical use cases include scale modeling, 3D print post-processing, woodworking, resin work, and small-scale DIY projects. It is used for tasks such as removing support marks, refining joints, and smoothing surface imperfections across plastic, resin, wood, and metal components.

Key Features

Compact cordless form factor: Palm-sized design intended for one-handed use in detailed work.

Linear motor system: Delivers up to 13,000 strokes per minute with direct reciprocating motion.

Interchangeable sanding heads: Eight head shapes for flat areas, edges, corners, and curved surfaces.

Full grit range included: Eight sanding grits supporting rough shaping through to fine finishing.

Low vibration operation: Designed to improve control and reduce fatigue during longer sessions.

NeoSander replaces bulkier sanding setups with a more portable option aimed at precision-focused work, particularly in small or intricate projects where control is critical.

Availability

NeoSander is available now through:

HOZO Amazon Store: https://www.amazon.com/dp/B0GY7X66J6
HOZO Official Website: https://hozodesign.com/products/neosander

About HOZO

HOZO is a technology and design company dedicated to developing innovative tools that combine precision engineering with user-centered design. Serving creators, makers, and professionals worldwide, HOZO continues to deliver intelligent, user-friendly solutions that simplify complex creative tasks while improving efficiency and accuracy.

Media Contact

Company: Hozo Design Co., Limited
Contact Person: Edith Pan
City: Hong Kong
Country: China
Website: https://hozodesign.com
Email: edith@hozodesign.com 

Source